University Hospitals Ventures

David Sylvan is President of UH Ventures and also the Chief Strategy, Innovation & Marketing Officer for University Hospitals. The investment team includes Neil Wyant (Vice President and Managing Director) and Matthew Zenker (Director of Deal Flow and Investment), who oversee deal sourcing and diligence (per the firm's website).

UH Ventures is the innovation and commercialization arm of University Hospitals, a $6B health system. It operates as an internal unit, not as a separate legal entity. Its activities include technology transfer, product development, direct investments, joint ventures, and partnerships — all aligned with the health system's strategic priorities (per the firm's website).

No, UH Ventures pursues both inside-out and outside-in strategies. The inside-out pipeline commercializes inventions from UH caregivers. The outside-in team sources external technologies and startups that can address system needs. The team evaluates opportunities from anywhere, though priority goes to solutions that improve patient care or operational efficiency at UH (per the firm's website).

UH Ventures focuses on early-stage technologies, from invention disclosure and proof-of-concept to pilot and commercialization. It uses direct investments, joint ventures, and co-development. The team also manages a grant program (the C-Path Translational Therapeutics Accelerator example) and works with external partners to fund later-stage opportunities (per the firm's website).

UH Ventures does not publicly disclose an AUM or a dedicated fund size. Its investment activities are integrated into the overall University Hospitals budget and strategy. The team deploys capital through direct investments, joint ventures, and partnerships, but no separate fund or AUM figure is published (per the firm's website).